USA flag logo/image

An Official Website of the United States Government

PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75993
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AR052986
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PARION SCIENCES, INC.
2525 MERIDIAN PKY, STE 260 DURHAM, NC 27713-2261
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME
Agency: HHS
Contract: 9R44DE020042-02A1
Award Amount: $379,296.00
 

Abstract:

DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involvement due to autoantibody production or pre- existing co nnective tissue disorder. Over time, progressive infiltration of lacrimal and salivary glands by mononuclear cells leads to diminished secretions, with resultant xerostomia (dry mouth) and xeropthalmia (dry eye) being the most prevalent symptoms. In Sjogre n's patients, xerostomia leads to significant discomfort; interferes with activities such as speaking, chewing, and sleeping; and can result in numerous secondary clinical manifestations. Use of currently available treatments for xerostomia, including sali va substitutes and centrally acting parasympathomimetic secretagogues such as pilocarpine and cevimeline, provide transient relief, but patients often find these remedies costly, ineffective, inconvenient, and associated with uncomfortable side effects. Pa rion Sciences is developing 552-02, a novel epithelial sodium channel (ENaC) blocker, as a therapeutic for the indication of dry mouth. A 28-day, randomized, double-blind, placebo-controlled crossover, safety study (205S) was conducted to evaluate the safe ty and efficacy of 552-02 formulated as an oral rise. In study 205S, the oromucosal formulation of 552-02 was safe and well tolerated when administered 6 times daily for 28 days to patients with dry mouth associated with Sjogren's syndrome. Despite the sma ll sample size in this exploratory study (n=30), patients' assessments of changes from baseline in symptoms of dry mouth using visual analog scales indicated 552-02 efficacy for mouth dryness, tongue dryness, and the ability to sleep, and for overall sympt oms of dry mouth (global assessment). Based on these results, Parion is continuing to develop its xerostomia program and is planning a follow-up Phase II study that will be optimized to increase efficacy and patient convenience. Specifically, the proposed study (207S) is powered for efficacy measures and includes an increase in concentration of 552-02 and new trial design. Study 207S is a necessary step in the overall development program for 552-02 as a novel therapy for treating the symptoms of dry mouth a ssociated with Sjvogren's syndrome. PUBLIC HEALTH RELEVANCE: Sjogren's syndrome is a disease that is, in part, characterized by severe dry mouth and dry eye. In Sjogren's patients, severe dry mouth leads to significant discomfort; interferes with a ctivities such as speaking, chewing, and sleeping; and can result in other numerous disease conditions. Parion Sciences is developing a new drug that will be given as a mouth spray for the treatment of dry mouth associated with Sjogren's syndrome.

Principal Investigator:

Karl Donn

Business Contact:

Small Business Information at Submission:

PARION SCIENCES, INC.
PARION SCIENCES, INC. 2525 MERIDIAN PKY, STE 260 DURHAM, NC 27713

EIN/Tax ID: 562193488
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No